Видео ютуба по тегу Mitapivat

Luspatercept and Mitapivat for the treatment of inherited anemias
Luspatercept and Mitapivat for the treatment of inherited anemias
Insights into the mechanism of action and applications of mitapivat
Insights into the mechanism of action and applications of mitapivat
Updates from the ENERGIZE study of mitapivat in non-transfusion-dependent alpha-/beta-thalassemia
Updates from the ENERGIZE study of mitapivat in non-transfusion-dependent alpha-/beta-thalassemia
Mechanism of action of mitapivat and its potential in the treatment of SCD
Mechanism of action of mitapivat and its potential in the treatment of SCD
Hanny Al-Samkari: Mitapivat for Patients With Pyruvate Kinase Deficiency
Hanny Al-Samkari: Mitapivat for Patients With Pyruvate Kinase Deficiency
Mitapivat in SCD: one-year follow-up results from the ESTIMATE trial
Mitapivat in SCD: one-year follow-up results from the ESTIMATE trial
What you NEED to know about MOA of PYRUKYND (mitapivat) -- approved for PK Deficiency Anemia
What you NEED to know about MOA of PYRUKYND (mitapivat) -- approved for PK Deficiency Anemia
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
The promise of pyruvate kinase activators, such as mitapivat, for treating SCD and thalassemia
The promise of pyruvate kinase activators, such as mitapivat, for treating SCD and thalassemia
Opportunities to combine mitapivat with other therapies in clinical trials
Opportunities to combine mitapivat with other therapies in clinical trials
Mitapivat increases β-thalassemic erythroblast energy production and oxidative stress responsiveness
Mitapivat increases β-thalassemic erythroblast energy production and oxidative stress responsiveness
SATISFY: mitapivat in patients with erythrocyte membranopathies
SATISFY: mitapivat in patients with erythrocyte membranopathies
The potential of mitapivat in thalassemia: results of the ENERGIZE and ENERGIZE-T trials
The potential of mitapivat in thalassemia: results of the ENERGIZE and ENERGIZE-T trials
ENERGIZE-T: a Phase III study of mitapivat in transfusion-dependent alpha- or beta-thalassemia
ENERGIZE-T: a Phase III study of mitapivat in transfusion-dependent alpha- or beta-thalassemia
Mitapivat: mechanism of action and updates with this agent in thalassemia treatment
Mitapivat: mechanism of action and updates with this agent in thalassemia treatment
Agios Pharmaceuticals Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Dissemination Pills: SATISFY Trial: Mitapivat & PROMs in Rare Anemias (NCT05935202)
Dissemination Pills: SATISFY Trial: Mitapivat & PROMs in Rare Anemias (NCT05935202)
Advances in the treatment of SCD & thalassemia: luspatercept, mitapivat, gene therapy, and more
Advances in the treatment of SCD & thalassemia: luspatercept, mitapivat, gene therapy, and more
Update on the ENERGIZE trial of mitapivat in NTD alpha- and beta-thalassemia
Update on the ENERGIZE trial of mitapivat in NTD alpha- and beta-thalassemia
Advances in pyruvate kinase activators for MDS and PKD: mitapivat & AG946
Advances in pyruvate kinase activators for MDS and PKD: mitapivat & AG946
Exploring mitapivat in thalassemia & SCD: the potential upcoming approval of the agent
Exploring mitapivat in thalassemia & SCD: the potential upcoming approval of the agent
Know about the Drug:Mitapivat
Know about the Drug:Mitapivat
The potential of mitapivat for treating thalassemia
The potential of mitapivat for treating thalassemia
Will Agios Transform Pediatric PK Deficiency Treatment? Mitapivat Data & Q4 Results Unveiled!
Will Agios Transform Pediatric PK Deficiency Treatment? Mitapivat Data & Q4 Results Unveiled!
Agios CEO Jackie Fouse on FDA Orphan Drug Designated Mitapivat
Agios CEO Jackie Fouse on FDA Orphan Drug Designated Mitapivat